Erman Akkus
@erman_akkus
MD, medical #oncology, internal #medicine specialist, @AnkaraUni, Sharing&discussing #cancer science 🧬
ID: 247382528
04-02-2011 17:44:35
1,1K Tweet
2,2K Takipçi
854 Takip Edilen
📢Colorectal cancer abstracts in #ESMO24 ESMO - Eur. Oncology ✅515MO - Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) ✅516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line
📘Early-Onset Colorectal Cancer: From laboratory to the clinic ESMO - Eur. Oncology ✅A comprehensive review ⁉️A lot of questions remain to be answered in terms of biology, agresiveness, prognosis and screening 👉doi.org/10.1016/j.ctrv… Oncology Advance Dr. Cathy Eng Cihangir Akyol, MD Beliz Bahar Karaoğlan
Alternative medicine therapies without standard treatments in non-metastatic patients are associated with higher risk of death about 150% ❗️ Even, in breast and colorectal cancer, it is roughly 300-400% ❗️ Yüksel Ürün ESMO - Eur. Oncology ASCO National Cancer Institute
One-question #oncpoll ❓ Would you give adjuvant chemotherapy for resected T2/3-N0 MSI-H gastric cancer ? Cancer Data etc Lizzy Smyth #cancer #oncology #MedX
⚡️Top 10 GI abstracts #ESMO24 ESMO - Eur. Oncology ✅by #OncoAlert 👇 Stay tuned 📢
The latest and greatest in #GIonc will be presented soon ESMO - Eur. Oncology #ESMO24 in #Barcelona 🇪🇸 Humbled to contribute alongside the prolific Erman Akkus and Gil Morgan, MD Make sure you follow OncoAlert🚨 for updates leading up to, through and beyond the conference.
This evening Henning Köhne gave a very nice speech and long excellent discussion on metastatic CRC treatment in Ankara. 🚨Most of the recommendations on RAS mutant status and sideness are based on retrospective subgroup analyses DKFZ Klinikum Oldenburg Enes Erul MD Onur Baş, MD Beliz Bahar Karaoğlan
Top 10 lung cancer abstracts #ESMO24 ESMO - Eur. Oncology by #OncoAlert ✅
🧬Mismatch repair in pancreatic cancer JAMA Oncology ✅Although it is rare, MSI should be tested in pancreatic cancer ✅Median IO duration: 27.7 months, DCR: 80% 👉doi:10.1001/jamaoncol.2024.3651 Catherine O’Connor Emily Harrold Wungki Park, MD MS Eileen M O’Reilly #cancer #Oncology #MedX
Young females had the highest Average Annual Percentage Changes for pancreatic cancer in individuals younger than 35. Also shown in gastric cancer, myeloma, and colorectal malignancies. BMC Medicine pubmed.ncbi.nlm.nih.gov/39232785/
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on The Lancet Oncology thelancet.com/journals/lanon… This phase 3 randomized controlled trial (CCTG HE1) aimed to